Max Weight Loss20.9%
Studies12
Participants8,750
StatusAvailable
Tirzepatide
Dual GIP and GLP-1 Receptor Agonist
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Available as FDA-approved Mounjaro® for Type 2 diabetes and Zepbound® for weight management and obstructive sleep apnea. It provides superior weight loss and glycemic control compared to single-pathway medications through its unique dual mechanism of action.
Clinical Safety Profile
Reported Side Effects
Nausea (most common, dose-related)
Diarrhea and gastrointestinal upset
Decreased appetite
Vomiting and acid reflux
Injection site reactions
Fatigue and headache
Constipation
Abdominal pain
Side Effect Management (Clinical Trial Data)
Nausea
Common
29.8%
Diarrhea
Common
21.2%
Decreased Appetite
Common
18.7%
Vomiting
Common
15.3%
Injection Site Reactions
Infrequent
8.9%
Side Effect Management Strategies
Nausea: Take with food, smaller meals, ginger supplements
Vomiting: Slower dose escalation, anti-emetics if severe
Diarrhea: Adequate hydration, probiotics, bland diet
Constipation: Increase fiber intake, adequate fluids, light exercise
Clinical Safety Metrics
Excellent
Overall Safety Rating
15.3%
Discontinuation Rate
FDA APPROVED
Approved Status
CONTRAINDICATIONS
• Medullary thyroid carcinoma (personal/family history)
• Multiple Endocrine Neoplasia Type 2
• Known hypersensitivity to tirzepatide
• Severe gastroparesis
Medical Disclaimer
Tirzepatide is FDA-approved as Mounjaro® for Type 2 diabetes and Zepbound® for chronic weight management. This information is for educational purposes and should not replace consultation with healthcare providers. Individual results may vary. Prescribing information and medical supervision are required for all therapeutic uses.